CYCN
Closed
Cyclerion Therapeutics Inc
3.1
+0.2 (+6.87%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.91
Day's Range: 2.8459 - 3.1529
Send
sign up or login to leave a comment!
When Written:
0.4339
Cyclerion Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of treatments for serious and orphan diseases. The company is headquartered in Cambridge, Massachusetts, and was founded in 2018 as a spin-off from Ironwood Pharmaceuticals.
Cyclerion Therapeutics is developing a pipeline of small molecule drugs that target soluble guanylate cyclase (sGC), an enzyme that plays a critical role in regulating cardiovascular, neurological, and inflammatory signaling pathways. The company's lead drug candidate, CY6463, is being developed for the treatment of neuropathic pain and is currently in Phase 2 clinical trials.
Cyclerion Therapeutics is also developing other sGC stimulators for the treatment of various diseases, including pulmonary arterial hypertension, heart failure, and diabetic nephropathy. The company has partnerships with several pharmaceutical companies, including Akebia Therapeutics, Ironwood Pharmaceuticals, and Vertex Pharmaceuticals.
As of 2021, Cyclerion Therapeutics has a market capitalization of approximately $250 million and is listed on the NASDAQ stock exchange under the ticker symbol "CYCN."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Cyclerion Therapeutics is developing a pipeline of small molecule drugs that target soluble guanylate cyclase (sGC), an enzyme that plays a critical role in regulating cardiovascular, neurological, and inflammatory signaling pathways. The company's lead drug candidate, CY6463, is being developed for the treatment of neuropathic pain and is currently in Phase 2 clinical trials.
Cyclerion Therapeutics is also developing other sGC stimulators for the treatment of various diseases, including pulmonary arterial hypertension, heart failure, and diabetic nephropathy. The company has partnerships with several pharmaceutical companies, including Akebia Therapeutics, Ironwood Pharmaceuticals, and Vertex Pharmaceuticals.
As of 2021, Cyclerion Therapeutics has a market capitalization of approximately $250 million and is listed on the NASDAQ stock exchange under the ticker symbol "CYCN."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!